2511 Stock Overview
An investment holding company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HighTide Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.41 |
| 52 Week High | HK$8.64 |
| 52 Week Low | HK$1.38 |
| Beta | 0 |
| 11 Month Change | -72.41% |
| 3 Month Change | -75.09% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2511 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -7.2% | -0.7% | -1.0% |
| 1Y | n/a | -34.6% | 0.7% |
Return vs Industry: Insufficient data to determine how 2511 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2511 performed against the Hong Kong Market.
Price Volatility
| 2511 volatility | |
|---|---|
| 2511 Average Weekly Movement | 24.2% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2511's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2511's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Liping Liu | www.hightidetx.com |
HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis; in phase III clinical trial to treat type 2 diabetes mellitus; is in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease.
HighTide Therapeutics, Inc. Fundamentals Summary
| 2511 fundamental statistics | |
|---|---|
| Market cap | HK$725.83m |
| Earnings (TTM) | -HK$1.01b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 2511 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2511 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥939.31m |
| Earnings | -CN¥939.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.5% |
How did 2511 perform over the long term?
See historical performance and comparison